Insights gained primarily from in vitro models of p53 regulators and effectors within our research program have led to a critical need for in vivo validation and the ability to gain further understanding using in vivo models. The phenotypes that are actively being examined in the p53 paradigm are no longer simply a matter of cell death, growth arrest or senescence. Instead, the role of p53 activation in vivo will likely have different consequences In different cell and tissue types and will likely differ with regard to developmental stages. The Cell and Animal Model Core (Core B) will derive and maintain human and mouse cell lines as well as adequate stocks of early passage aliquots of frozen primary cells utilized by the projects. It will serve as a repository for monoclonal antibodies and validated RNAi reagents. The Core will also acquire and maintain steadily used mouse models (transgenic, knockouts, etc.) and primary cells derived from these mice for distribution to the investigators in the Program. The research efforts of our productive and collaborative program greatly benefit from an in vivo models component, which maintains small breeding colonies of critically needed mouse strains for genetic and cell biologic investigations by our investigators. The high cost of animal studies in barrier facilities can be reduced substantially by the availability of shared technical support for mouse breeding and genetic analyses and for shared immunohistochemistry. The cost effectiveness is further emphasized by the shared use of the same genetically modified strains by several investigators and projects within the Program. Lastly, the core will provide expertise and guidance in the preparation of tissue and/or embryos for analyses of gene expression (protein and mRNA in situ).
The interactive and collaborative nature of the Program is enhanced by the resources provided by the Cell and Animal Model Core (Core B). This plays an essential role in facilitating the ongoing studies into pathways that are critical for the roles of p53 in tumor suppression, innate immunity and DNA damage responses.
|Pappas, Kyrie; Xu, Jia; Zairis, Sakellarios et al. (2017) p53 Maintains Baseline Expression of Multiple Tumor Suppressor Genes. Mol Cancer Res 15:1051-1062|
|Ou, Yang; Wang, Shang-Jui; Li, Dawei et al. (2016) Activation of SAT1 engages polyamine metabolism with p53-mediated ferroptotic responses. Proc Natl Acad Sci U S A 113:E6806-E6812|
|Guernet, Alexis; Mungamuri, Sathish Kumar; Cartier, Dorthe et al. (2016) CRISPR-Barcoding for Intratumor Genetic Heterogeneity Modeling and Functional Analysis of Oncogenic Driver Mutations. Mol Cell 63:526-38|
|Meslamani, Jamel; Smith, Steven G; Sanchez, Roberto et al. (2016) Structural features and inhibitors of bromodomains. Drug Discov Today Technol 19:3-15|
|Hwang, So-Young; Deng, Xianming; Byun, Sanguine et al. (2016) Direct Targeting of ?-Catenin by a Small Molecule Stimulates Proteasomal Degradation and Suppresses Oncogenic Wnt/?-Catenin Signaling. Cell Rep 16:28-36|
|Shi, D; Dai, C; Qin, J et al. (2016) Negative regulation of the p300-p53 interplay by DDX24. Oncogene 35:528-36|
|Tavana, Omid; Li, Dawei; Dai, Chao et al. (2016) HAUSP deubiquitinates and stabilizes N-Myc in neuroblastoma. Nat Med 22:1180-1186|
|Wang, Donglai; Kon, Ning; Lasso, Gorka et al. (2016) Acetylation-regulated interaction between p53 and SET reveals a widespread regulatory mode. Nature 538:118-122|
|Mungamuri, Sathish Kumar; Qiao, Rui F; Yao, Shen et al. (2016) USP7 Enforces Heterochromatinization of p53 Target Promoters by Protecting SUV39H1 from MDM2-Mediated Degradation. Cell Rep 14:2528-37|
|Muñoz-Fontela, César; Mandinova, Anna; Aaronson, Stuart A et al. (2016) Emerging roles of p53 and other tumour-suppressor genes in immune regulation. Nat Rev Immunol 16:741-750|
Showing the most recent 10 out of 101 publications